Latest Breaking News On - Juha karttunen - Page 7 : comparemela.com

Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine

Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumorsCLEVER-1 targeting is safe and well-tolerated with no serious adverse effectsBexmarilimab induced macrophage activation and increased IFNɣ signaling in patients who achieved disease control and prolonged survival TURKU, Finland and BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical co

United statesSandy jamiesonMary jane elliottChristopher goldenLindsey nevilleDavid daleyJuha karttunenPetri bonoJo turnerPeel huntCairn financial advisersFaron pharmaceuticals ltdFirst northCell reportsCell reports medicineChief medical officer

Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS

MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase 2 part of the study will recruit 32 HMA-failed MDS patients for 1:1 dose randomization with possible data release after 20 patients have received more than two treatment cycles Company announcement, Inside Information TURKU, Finland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) Faron Pharmaceutical

United statesEteläuomen läiMary jane elliottLindsey nevilleSandy jamiesonDavid daleyMika kontroMarkku jalkanenJo turnerJuha karttunenChristopher goldenDrug administrationPeel huntCairn financial advisersFaron pharmaceuticals ltdHelsinki university hospital comprehensive cancer center

Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting

Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diego convention centerSan diegoEteläuomen läiJo turnerMary jane elliottSandy jamiesonLindsey nevilleMika kontroJuha karttunenChristopher goldenDavid daleyPeel huntCairn financial advisersAmerican society of hematologyUniversity of texas md anderson cancer center

Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 ("MAR") AND ARTICLE 7

United kingdomUnited statesEteläuomen läiJo turnerJuha karttunenDavid daleySandy jamiesonTimo syrjJim obrienLindsey nevilleMary jane elliottCompany the launch announcementFaron pharmaceuticals ltd firstFinland branch carnegieDirectors of the companyCommission delegated directive

Composition of KH Group Plc s Shareholders Nomination Board

KH Group Plc Stock Exchange Release 9 October 2023 at 2:00 pm EEST Composition of KH Group Plc’s Shareholders’ Nomination Board The Shareholders’ Nomination Board of KH Group Plc has been.

Eteläuomen läiNorthern ostrobothniaSimon hallqvistJohanna takanenMikko laakkonenJuha karttunenKh group plc shareholder nomination boardIkh groupCompany board of directorsKh group plcStock exchangeExchange releaseShareholder nomination boardNomination boardAnnual general meetingPreato capital